Beijing Beilu Pharmaceutical Co., Ltd

300016

CNE000001QK9

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-06-06 pm EDT			5-day change	1st Jan Change
4.59 ^CNY	+2.23%		-10.87%	-35.53%

Apr. 21	Beijing Beilu Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Feb. 29	Beijing Beilu Pharmaceutical Co., Ltd Signed a Letter of intent to acquire 80% stake in Chengde Tianyuan Pharmaceuticals Co.,Ltd from Goldenmax International Group Ltd. for CNY 248 million.	CI

Beijing Beilu Pharmaceutical Co.,Ltd Announces the Implementation of Cash Dividend for 2019, Payable on 15 June 2020

June 08, 2020 at 03:34 pm EDT

Beijing Beilu Pharmaceutical Co.,Ltd announced the implementation of cash dividend of CNY 0.70000000 (taxes included) per A share for 2019. Record date is 12 June 2020 with ex-dividend date on 15 June 2020 and payable date is 15 June 2020.

Latest news about Beijing Beilu Pharmaceutical Co., Ltd

Beijing Beilu Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 21	CI
Beijing Beilu Pharmaceutical Co., Ltd Signed a Letter of intent to acquire 80% stake in Chengde Tianyuan Pharmaceuticals Co.,Ltd from Goldenmax International Group Ltd. for CNY 248 million.	Feb. 28	CI
Beijing Beilu Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
Beijing Beilu Pharmaceutical Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-27	CI
Beijing Beilu Pharmaceutical Co., Ltd Announces Cash Dividend on A Shares for 2022, Payable on May 25, 2023	23-05-18	CI
Beijing Beilu Pharmaceutical Co., Ltd Approves Cash Dividend for 2022	23-05-17	CI
Beijing Beilu Pharmaceutical Co., Ltd Proposes Final Cash Dividend for the Year 2022	23-04-24	CI
Beijing Beilu Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-23	CI
Beijing Beilu Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-26	CI
Beijing Beilu Pharmaceutical Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-26	CI
Beijing Beilu Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-27	CI
Beijing Beilu Pharmaceutical Co.,Ltd Announces the Implementation of Cash Dividend for 2019, Payable on 29 April 2022	22-04-25	CI
Beijing Beilu Pharmaceutical Co., Ltd Elects Board Members	22-04-21	CI
Beijing Beilu Pharmaceutical Co., Ltd. Announces Final Cash Dividend for Year 2021	22-03-30	CI
Beijing Beilu Pharmaceutical Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-29	CI
Beijing Beilu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-27	CI
Beijing Beilu Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-19	CI
Beijing Beilu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-28	CI
Beijing Beilu Pharmaceutical Co., Ltd. Approves Profit Distribution for 2020	21-04-09	CI
Beijing Beilu Pharmaceutical : Proposes Final Dividend for 2020	21-03-21	MT
Beijing Beilu Pharmaceutical Co., Ltd. Announces Profit Distribution Proposal for 2020	21-03-19	CI
Beijing Beilu Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-18	CI
Beijing Beilu Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2020	20-10-29	CI
Beijing Beilu Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2020	20-08-07	CI
Beijing Beilu Pharmaceutical Co.,Ltd Announces the Implementation of Cash Dividend for 2019, Payable on 15 June 2020	20-06-08	CI

Chart Beijing Beilu Pharmaceutical Co., Ltd

Duration

Period

Chart Beijing Beilu Pharmaceutical Co., Ltd

More charts

Company Profile

Beijing Beilu Pharmaceutical Co., Ltd is a China-based company principally engaged in the research, development, production and distribution of contract medium products, anti-diabetic products and anti-anxiety products. The Companyâs main products include gadopentetate dimeglumine injection, iohexol injection, Iodoparol injection, Iodixanol injection, ferric ammonium citrate effervescent granules, repaglinide tablets, glimepiride tablets, Jiuwei Zhenxin granules, among others. The Company mainly distributes its products in domestic market.

Sector

Pharmaceuticals

Calendar

2024-07-25 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BEIJING BEILU PHARMACEUTICAL CO., LTD	-35.53%	312M
ELI LILLY AND COMPANY	+45.82%	765B
JOHNSON & JOHNSON	-6.16%	354B
MERCK & CO., INC.	+19.86%	331B
ABBVIE INC.	+9.32%	299B
ASTRAZENECA PLC	+18.45%	248B
ROCHE HOLDING AG	-0.78%	219B
NOVARTIS AG	+11.88%	216B
AMGEN INC.	+5.90%	164B
PFIZER, INC.	-0.73%	162B